The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Abuzarova G.R.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Sarmanaeva R.R.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Lapina S.E.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kuznetsov S.V.

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia, Moscow

Strong opioid analgesics in therapy for chronic pain syndrome. Which drug should be preferred?

Authors:

Abuzarova G.R., Sarmanaeva R.R., Lapina S.E., Kuznetsov S.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2017;6(6): 62‑71

DOI: 10.17116/onkolog20176662-71

Read: 181085 times

Download PDF (RU)
Contact the author
Table of contents

STRONG OPIOID ANALGESICS IN THERAPY FOR CHRONIC PAIN SYNDROME. WHICH DRUG SHOULD BE PREFERRED?
STRONG OPIOID ANALGESICS IN THERAPY FOR CHRONIC PAIN SYNDROME. WHICH DRUG SHOULD BE PREFERRED?

To cite this article:

Abuzarova GR, Sarmanaeva RR, Lapina SE, Kuznetsov SV. Strong opioid analgesics in therapy for chronic pain syndrome. Which drug should be preferred? P.A. Herzen Journal of Oncology. 2017;6(6):62‑71. (In Russ.)
https://doi.org/10.17116/onkolog20176662-71

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

According to current Russian recommendations for pain therapy in palliative patients, the use of opioid analgesics is justified as necessary in treating chronic pain syndrome (CPS). However, the side effects of the agents, which accompany opioid therapy, often limit their efficacy and reduce quality of life in patients. Until recently, there have been only two highly potent opioid drugs, such as morphine (tablets, capsules) and TTS fentanyl, to treat severe CPS in our practice. A third drug (oxycodone/naloxone) has been available since 2017. The review considers indications for the use of this or that drug in terms of their pharmacokinetics and metabolism, their characteristics of their dosage forms, and foreign experience of their use.

Keywords:

chronic pain therapy
strong opioid analgesics
pharmacology
clinical application

Authors:

Abuzarova G.R.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Sarmanaeva R.R.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Lapina S.E.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Kuznetsov S.V.

P.A. Herzen Moscow Oncology Research Institute, Ministry of Health of Russia, Moscow

Close metadata

References:

  1. Davis MP. Opioids for cancer pain. (2 ed.). Oxford UK: Oxford University Press; 2009. https://doi.org/10.1093/med/9780199236640.001.0001
  2. The instruction to the drug morphine sulfate on the official website of the State register of medicines. (In Russ.) http://grls.rosminzdrav.ru/
  3. Caraceni A, Hanks G, Kaassa S, Bennett MI, Brunelli С, Cherny N et al. Use of Opioid Analgesics in the Treatment of Cancer Pain: Evidence-based Recommendations from the EAPC. Lancet Oncol. 2012;13:e58-e68. http://www.eapcnet.eu https://doi.org/10.1016/s1470-2045(12)70040-2
  4. National Institute for Health and Clinical Effectiveness (NICE). Guide to the Methods of Technology Appraisal [reference N0515] (2004). http://www.dft.gov.uk/dvla/medical/ataglance.aspx
  5. Swarm Robert A, Anghelescu DL et al. National comprehensive cancer network (NCCN) Guidelines Version 1.2017 Panel Members Adult Cancer Pain Clinical practice Guidelines in oncology, 2017. https://utah.pure.elsevier.com/en/publications/adult-cancer-pain-clinical-practice-guidelines-in-oncology
  6. Twycross R, Wilcock A, Howard P. PCF5+, Palliative Care Formulary September 2015. includes monographs and: www.palliativedrugs.com. https://doi.org/10.1177/0269216312450126
  7. World Health Organization: Cancer pain relief: with a guide to opioid availability. 2nd edition. Geneva; 1996. http://www.who.int/cancer/palliative/painladder/en
  8. Bandieri E, Romero M, Ripamonti CI, Artioli F, Sichetti D, Fanizza C et al. Randomized Trial of Low-Dose Morphine Versus Weak Opioids in Moderate Cancer Pain. Journal of clinical oncology. 2015. December 7. https://doi.org/10.1200/jco.2015.61.0733
  9. Dean L. Tramadol Therapy and CYP2D6 Genotype. Medical Genetics Summaries. September 10, 2015. https://www.ncbi.nlm.nih.gov/books/NBK315950/
  10. Care Quality Commission and NHS England (2013) Safer use of controlled drugs — preventing harms from fentanyl and buprenorphine transdermal patches. Use of controlled drugs supporting information. www.cqc.org.uk https://doi.org/10.1007/s40278-016-16664-2
  11. Fentanyl transdermal patch and fatal adverse reactions. Health. Canada. Canadian Adverse Reaction Newsletter. 2008;18(3):1-2. https://doi.org/10.2165/00128415-200811840-00003
  12. FDA.2007. Fentanyl transdermal system (marketed as Duragesic) Information. Post market drug safety information for patients and providers. www.fda.gov/Drugs/DrugSafety. https://doi.org/10.2165/00128413-200715780-00059
  13. MHRA. 2008. Fentanyl patches: serious and fatal overdose from dosing errors, accidental exposure, and inappropriate use. Drug Safety Update. 2. www.mhra.gov.uk/safetyinformation
  14. The instruction to TTS fentanyl on the official website of the State register of medicines. (In Russ.) http://grls.rosminzdrav.ru
  15. Tassinari D, Sartori S, Tamburini E, Scarpi E, Raffaeli W, Tombesi P et al. Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature. Journal of Palliative Medicine. 2008;11:492-501. https://doi.org/10.1089/jpm.2007.0200
  16. Hannon B, Zimmermann C, Bryson JR. The role of fentanyl in refractory opioid-related acute colonic pseudo-obstruction. Journal of Pain and Symptom Management. 2013;45:e1-3. https://doi.org/10.1016/j.jpainsymman.2012.11.002
  17. Koo HC, Moon JH, Choi HJ, Hwang KH, Maeng HJ, Kim HK et al. Effect of transdermal fentanyl patches on the motility of the sphincter of oddi. Gut and Liver. 2010;4:368-372. https://doi.org/10.5009/gnl.2010.4.3.368
  18. Nomura M, Inoue K, Matsushita S, Takahari D, Kondoh C, Shitara K, et al. Serum concentration of fentanyl during conversion from intravenous to transdermal administration to patients with chronic cancer pain. Clin J Pain. 2013;29(6):487-491. https://doi.org/10.1097/ajp.0b013e318266f6a5
  19. Marquardt KA, Tharratt RS, Musallaml NA. Fentanyl remaining in a transdermal system following three days of continuous use. Annals of Pharmacotherpy. 1995;29:969-971. https://doi.org/10.1177/106002809502901001
  20. Tarja Heiskanen, Sorjo Mätzke, Soile Haakana, Merja Gergov, Erkki Vuori, Eija Kalso. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144:218-222. https://doi.org/10.1016/j.pain.2009.04.012
  21. Jonathan Hadgraft, Majella E Lane. Skin permeation: the years of enlightenment. International Journal of Pharmaceutics. 2005;305(1-2):2-12. https://doi.org/10.1016/j.ijphar.2005.07.014
  22. Wolfgang Korte, Noémi de Stoutz, Rudolf Morant. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short and long term experiences in a prospective study of 39 patients. Journal of Pain and Symptom Management. 1996;11(3):139-146. https://doi.org/10.1016/0885-3924(95)00162-x
  23. Clinical guidelines: chronic pain syndrome in adult patients requiring palliative care. 2016. Minzdrav RF, Moscow, 59 p. (In Russ.) http://cr.rosminzdrav.ru/schema
  24. Ans PE Vielvoye-Kerkmeer, Carlien Mattern, Martin P Uitendaal. Transdermal fentanyl in opioid-naive cancer pain patients: an open trial using transdermal fentanyl for the treatment of chronic cancer pain in opioid-naive patients and a group using codeine. Journal of Pain and Symptom Management. 2000;19(3):185-192. https://doi.org/10.1016/s0885-3924(99)00152-9
  25. Mohamed Omar Tawfik, Vladimir Bryuzgin, Galina Kourteva. Use of transdermal fentanyl without prior opioid stabilization in patients with cancer pain. Current Medical Research Opinion. 2004;20(3):259-267. https://doi.org/10.1185/030079903125003026
  26. Abuzarova GR. Diagnostika I differencirovannaya farmacoterepiya khronicheskogo bolevogo sindroma u oncologicheskih bolnyh. M.: GEOTAR-Media; 2015. (In Russ.)
  27. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. British Journal of Clinical Pharmacology. 1992;33(6):617-621. https://doi.org/10.1111/j.1365-2125.1992.tb04090.x
  28. Fraser B Ross, Steven C Wallis, Maree T Smith. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats. Pain. 2000;84(2):421-428. https://doi.org/10.1016/s0304-3959(99)00230-4
  29. Lynn Webster. Efficacy and safety of dual-opioid therapy in acute pain. Pain Medicine. 2012;13(Suppl.1):12-20. https://doi.org/10.1111/j.1526-4637.2012.01330.x
  30. Patricia Richards, Dennis Riff, Robin Kelen, Warren Stern. Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination (MoxDuo) in the treatment of postoperative pain. Journal of Opioid Management. 2011;7(3):217-228. https://doi.org/10.5055/jom.2011.0064
  31. Felix A de la Iglesia, Gary W Pace, Gary LWG Robinson, Nuo-Yu Huang, Warren Stern, Patricia Richards. Tolerability and efficacy of two synergistic ratios of oral morphine and oxycodone combinations versus morphine in patients with chronic noncancer pain. Journal of Opioid Management. 2012;8(2):89-98. https://doi.org/10.5055/jom.2012.0101
  32. Suzuki M, Sakurada T, Gotoh K, Watanabe S, Satoh N. Correlation between the administration of morphine or oxycodone and the development of infections in patients with cancer pain. American Journal of Hospice and Palliative Care. 2012;30(7):712-716. https://doi.org/10.1177/1049909112469823
  33. Tarja Heiskanen, Klaus T Olkkola, Eija Kalso. Effects of blocking CYP2D6 on oxycodone. Clinical Pharmacology and Therapeutics. 1998;64:603-611. https://doi.org/10.1016/s0009-9236(98)90051-0
  34. Lalovic B, Kharash E, Hoffer C, Risler L,Liuchen L, Shen D. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clinical Pharmacology and Therapeutics. 2006;79(5):461-479. https://doi.org/10.1016/j.clpt.2006.01.009
  35. Bruera E, Belzile M, Pituskin E, Fainsinger R, Darke A, Harsanyi Z, Babul N, Ford I. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. Journal of Clinical Oncology. 1998;16(10):3222-3229. https://doi.org/10.1200/jco.1998.16.10.3222
  36. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. British Journal of Cancer. 2003;89(11):2027-2030. https://doi.org/10.1038/sj.bjc.6601365
  37. Sandner-Kiesling A, Leyendecker P, Hopp M, Tarau L, Lejcko J, Meissner W, Sevcik P, Hakl M, Hrib R, Uhl R, Dürr H, Reimer K. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain. International Journal of Clinical Practice. 2010;64(6):763-774. https://doi.org/10.1111/j.1742-1241.2010.02360.x
  38. The instruction to the drug targin (oxycodone+naloxone) on the official website. (In Russ.) http://grls.rosminzdrav.ru
  39. Johannes Oppermann, Jan Bredow, Christian K Spies, Julia Lemken, Frank Unglaub, Christoph K Boese, Jens Dargel, Peer Eysel, Jan Zöllner. Effect of prolonged-released oxycodone/naloxone in postoperative pain management after total knee replacement: a nonrandomized prospective trial. Journal of Clinical Anesthesia. 2016;33:491-497. https://doi.org/10.1016/j.jclinane.2016.04.002
  40. Kuusniemi K, Zöllner J, Sjövall S, Huhtala J, Karjalainen P, Kokki M, Lemken J, Oppermann J, Kokki H. Prolonged-release Oxycodone/Naloxone in Postoperative Pain Management: From a Randomized Clinical Trial to Usual Clinical Practice. Journal of International Medical Research. 2012;40(5):1775-1793. https://doi.org/10.1177/030006051204000516
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.